Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
In his sixteenth annual letter, Fundsmith CEO Terry Smith reports that the Fundsmith Equity Fund rose by 0.8% in 2025, underperforming the MSCI World Index's 12.8% gain. Underperformance was driven...
— Terry Smith
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Novo Nordisk
Novo Nordisk experienced short-term headwinds as its recent financial guidance failed to meet consensus estimates. However, the manager...
The fund decided to completely sell its position in Novo Nordisk after experiencing a deterioration in the company's multi-year financial outlook. Despite buying the...